Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder characterised by the motor features of tremor, rigidity and bradykinesia. These features are associated with the loss of dopaminergic (DA) neurons in the substantia nigra pars compacta and the subsequent deficiency in striatal DA, which is required for the effective control of movements. However, there is evidence of a more diffuse pathology in PD [1] with other, non-DA neurotransmitter systems possibly playing a role [2-6]. Furthermore, PD is also associated with many non-motor features including behavioural and psychiatric problems such as dementia [7] sleep disturbances and fatigue [8], depression [9], addiction and compulsion [10] and psychosis [11].

PD is the second most common neurodegenerative disorder after Alzheimer’s disease (AD) [12, 13] occurring at a median age of 62.4 years although up to 10% of cases begins by the age of 40 [14]. PD is uncommon before the age of 40. The prevalence of PD increases with age from 1% to up to 3% after 80 years of age [15].

The pathological hallmark of PD is characterised by the DA neuronal loss together with the presence of ubiquinated protein deposits in the cytoplasm of neurons, called Lewy bodies [16, 17].

Brain imaging techniques provide a useful tool of in vivo investigation of the pathogenesis of PD and pathophysiology of PD processes. Positron Emission Tomography (PET) imaging is a nuclear medicine technique enabling the estimation of important physiological parameters, such as, glucose metabolism and neuroreceptor binding. In PET, radioisotopes bound to specific tracers are administered to an individual via an intravenous (IV) injection whereby the estimation of the distribution of the radiotracer over time in the brain can be calculated.

PET is a relatively expensive technique and to date is not widely available. However, it does offer high sensitivity with admirable spatial and...
PET neuroimaging for PD

Dopaminergic imaging

Presynaptic DA system imaging studies

Presynaptic DA terminal functionality can be investigated using PET by measuring aromatic amino acid decarboxylase (AADC) activity, dopamine transporter (DAT) activity and vesicular monoamine transporter (VMAT2) density.

$^{18}$F-DOPA PET is a radiotracer which can be used to assess AADC in the DA terminals [18]. As AADC activity permits the conversion of L-DOPA to DA, $^{18}$F-DOPA PET can be used as a measure of DA terminal functionality. This tracer has been utilised to assess the correlation between $^{18}$F-DOPA binding and motor disability. It has been demonstrated that striatal $^{18}$F-DOPA binding and motor disability (as measured by the Unified Parkinson's Disease Rating Scale [UPDRS]) are inversely correlated [19, 20], i.e. loss of DA terminals correlates with an increase in motor disability. There has also been an attempt with $^{18}$F-DOPA PET to delineate the pathogenesis of the core features of PD. This study reported $^{18}$F-DOPA uptake correlated with increased bradykinesia and rigidity scores but not with tremor scores, indicating that the pathogenesis for tremor may not be solely implicated by the DA system [21].

Furthermore, $^{18}$F-DOPA PET has been used to determine the stages of DA degeneration in PD. It has been demonstrated that the decline of DA function starts in the dorsalcaudal putamen contralateral to the clinically affected side [22] and that the rate of degeneration in the caudate nucleus is slower than that of the putamen [23] in early PD (Figure 1).

A recent $^{18}$F-DOPA PET study of ten early PD patients over 3 years reported reductions in $^{18}$F-DOPA binding in the putamen (8.1%), locus coeruleus (7.8%), globus pallidus interna (7.7%), caudate nucleus (6.3%) and hypothalamus (6.1%) [24].

Presynaptic synthesis and release of DA can be investigated by assessing the uptake and storage procedure of DA into the storage granules, which can be imaged using the radiotracer $^{11}$C-dihydratepironazene (DTBZ). This tracer labels the VMAT2 located in the presynaptic vesicles and as such can be used to evaluate the presynaptic status of the nigrostriatal system in PD [25]. It has been shown in advanced cases of PD that that striatal DTBZ binding decreases following L-3, 4-dihydroxypheynylalanine (L-DOPA) administration, likely reflecting an increase in vesicular DA levels [26]. Striatal uptake of DTBZ binding has also been shown to correlate with motor disability as measured by the UPDRS [27].

Labelling DATs, which are located on the presynaptic DA nerve terminals and facilitate the reuptake of released DA into the synaptic cleft, allows another method of assessing the presynaptic DA system. Various radiotracers have been developed in order to measure DAT in vivo, including, $^{11}$C-nomifensine, $^{11}$C-RT132, $^{11}$C-CFT, $^{18}$F-CFT [28-33]. These radiotracers are also capable of providing a measure of presynaptic DA terminal function [30, 34].

Postsynaptic DA system imaging studies

Postsynaptic DA receptors have a lower affinity to agonists than for antagonists and as such,
most PET studies utilise antagonist ligands [35]. A study of early PD patients used the radiotracers $^{11}$C-SCH23390 to assess striatal D$_1$ receptors and $^{11}$C-raclopride (RAC) to assess striatal D$_2$ receptors [36]. It was demonstrated that although the patient groups clinically presented with unilateral symptoms, there was a symmetric binding of $^{11}$C-SCH23390 across both hemispheres compared to an asymmetric binding of RAC (contralateral to the clinically affected side), suggesting that there is an abnormal binding of D$_2$ and not D$_1$ receptors in early PD. Similarly, a PET study using both $^{11}$C-SCH23390 and $^{18}$F-DOPA demonstrated no difference in D$_1$ receptor density between PD patients and healthy controls [37].

A two-scan RAC PET study has reported, in advanced PD cases that, improvement in bradykinesia and rigidity scores following oral DA medication administration were significantly correlated with reductions in RAC binding suggesting an effect of increased DA on the striatal D$_2$ receptors [38].

RAC PET has also been employed in de novo PD patients and demonstrated a 10-20% increase in D$_2$ receptor availability in the putamen contralateral to the clinically affected side whereas the caudate nucleus appears to remain relatively intact [32, 39-40].

Further RAC PET studies in previously untreated PD patients, has demonstrated that 3-4 months post-initiation of L-DOPA or lisuride treatment resulted in no change in D$_2$ receptor density [41]. However, 3-5 years post-treatment, RAC binding was demonstrated to be significantly reduced in the putamen and caudate nucleus compared to the baseline assessment [42]. This is indicative of a process of down-regulation of the striatal D$_2$ receptor binding in PD related to long-term treatment. It has been suggested that D$_2$ receptor changes observed in the putamen may be a consequence of the reduction in presynaptic DA nerve terminals as an association between RAC PET and $^{18}$F-DOPA binding has been found [43]. However, serial RAC PET studies have indicated that as the disease progresses, and thus patients are exposed to DA medications, D$_2$ binding in the putamen stabilises, whereas the caudate nucleus displays a reduction in D$_2$ binding by approximately 20% [40, 44-45].

Extrastriatal areas have also been investigated with RAC PET, with one study demonstrating a significant decrease in RAC binding in the hypothalamus of PD patients compared to a group of healthy controls [46] (Figure 2). This finding may be suggestive of a hypothalamic involvement in non-motor features commonly observed in PD, such as sleep, endocrine and autonomic disturbances.

RAC PET has also been employed in de novo PD patients and demonstrated a 10-20% increase in D$_2$ receptor availability in the putamen contralateral to the clinically affected side whereas the caudate nucleus appears to remain relatively intact [32, 39-40].

Further RAC PET studies in previously untreated PD patients, has demonstrated that 3-4 months post-initiation of L-DOPA or lisuride treatment resulted in no change in D$_2$ receptor density [41]. However, 3-5 years post-treatment, RAC binding was demonstrated to be significantly reduced in the putamen and caudate nucleus compared to the baseline assessment [42]. This is indicative of a process of down-regulation of the striatal D$_2$ receptor binding in PD related to long-term treatment. It has been suggested that D$_2$ receptor changes observed in the putamen may be a consequence of the reduction in presynaptic DA nerve terminals as an association between RAC PET and $^{18}$F-DOPA binding has been found [43]. However, serial RAC PET studies have indicated that as the disease progresses, and thus patients are exposed to DA medications, D$_2$ binding in the putamen stabilises, whereas the caudate nucleus displays a reduction in D$_2$ binding by approximately 20% [40, 44-45].

Extrastratal areas have also been investigated with RAC PET, with one study demonstrating a significant decrease in RAC binding in the hypothalamus of PD patients compared to a group of healthy controls [46] (Figure 2). This finding may be suggestive of a hypothalamic involvement in non-motor features commonly observed in PD, such as sleep, endocrine and autonomic disturbances.

RAC PET can also be used to assess DA release. This can be achieved by administering a pharmacological challenge, which inhibits DAT function, such as, methamphetamine. A study which employed this method in a group of healthy controls and a group of advanced PD patients reported that RAC binding was reduced in both groups but more pronounced in the PD group for the striatal regions (caudate nucleus: 8% v 17% and putamen: 7% v 25%) [47]. Moreover, RAC binding percentage reductions correlated with motor disability as measured by the UPDRS.

The endogenous release of DA can be assessed during the performance of motor tasks while in the scanner. A RAC PET study was able to assess DA release via a visuomotor task during which the subject may or may not gain a financial reward [48]. This study demonstrated with a group of healthy controls and a group of advanced PD patients that striatal DA release was apparent only in the healthy control group. However, in both groups, significant increases in the prefrontal cortical DA levels were detected.
indicating although striatal DA release during a motor task is impaired in early PD patients, it appears to be somewhat preserved in the prefrontal cortex.

**Non-dopaminergic imaging**

*Imaging the serotonergic system*

The suggestion that the serotonergic system may be implicated in PD has arisen from both post-mortem and biochemical studies [2, 3]. Various radiotracers have been developed in order to assess the integrity of the serotonergic system *in vivo* including, $^{11}$C-WAY100635, which specifically binds to the 5-HT$_{1A}$ receptors. These receptors are expressed both presynaptically and postsynaptically on 5-HT cell bodies in the midbrain raphe nuclei and on cortical pyramidal neurons and glia respectively. One study utilising this radiotracer has reported that 5-HT$_{1A}$ binding in the midbrain of PD patients was reduced by 29% compared to healthy controls [49]. Furthermore, the decreased 5-HT$_{1A}$ raphe binding was correlated with UPDRS tremor scores, but not rigidity or bradykinesia scores, suggesting that the serotonergic system may have a role in the development of tremor.

$^{11}$C-DASB and $^{11}$C-McN5652 are two radiotracers, which bind specifically to the serotonin transporter (SERT, 5-HTT) in the presynaptic terminals, thus providing a good measure of the integrity of serotonergic innervation. However to date, most studies utilising these radiotracers have reported that striatal serotonergic denervation is relatively moderate compared to striatal DA denervation [5, 33, 50]. It should be noted though that these studies are limited by the small sample size, which may implicate any correlations between regional binding measurements and motor disability scores. Furthermore, a study using single photon emission computed tomography (SPECT) has reported that striatal serotonergic innervation in PD is within normal range [51] suggesting that the complete picture of how the serotonergic system is implicated in PD is still unclear.

More recently, one $^{11}$C-DASB PET study with a larger sample size of 30 PD patients, has reported significant reductions in regional $^{11}$C-DASB binding in striatal, brainstem and cortical regions [6]. Furthermore, the authors demonstrated that $^{11}$C-DASB uptake was affected in the caudate nucleus, hypothalamus, thalamus and anterior cingulate cortex (ACC) early in the disease followed by the putamen, insular cortex, posterior cingulate cortex (PCC) and pre-frontal cortex (PFC) once PD is established, with advanced cases displaying further reductions in the ventral striatum, raphe nuclei and amygdala. These results are strongly suggestive of a progressive, non-linear serotonergic dysfunction in PD. Moreover, the regional $^{11}$C-DASB binding did not correlate with UPDRS scores, Hoehn and Yahr (H&Y) staging, disease duration or DA medication implying that serotonergic dysfunction does not influence motor disability.

Interestingly, findings from animal studies have suggested that the serotonin neurons possess the ability to convert exogenous L-DOPA to DA and subsequently store and release DA in an activity-dependent manner [52, 53].

*Imaging the cholinergic system*

$^{11}$C-PMP and $^{11}$C-MP4A are radiotracers which measure acetylcholinesterase (AChE) levels as they are analogues for acetylcholine and as such serve as a selective substrate for AChE hydrolysis thus providing a measure of the cholinergic system integrity [54]. These radiotracers can be used in conjunction with $^{11}$C-NMBP (a marker of postsynaptic muscarinic receptor availability) [55] to assess cholinergic function in dementia in PD.

*Imaging the opioid system*

$^{11}$C-diprenorphine is a radiotracer, which allows the measurement of $\mu$, $\kappa$ and $\delta$ opioid sites and has been demonstrated to show sensitivity to endogenous opioids [56], which are found in high densities in the caudate nucleus and putamen. Opioid neuropeptides are abundant in the basal ganglia [57] and it is known that the opioid system is involved in the pathophysiology of PD [58].

*Imaging the noradrenergic system*

There are currently no PET radiotracers to assess specifically the noradrenergic neurons *in vivo*. An attempt to use reboxetine derivatives as a marker of noradrenergic transporter (NAT) binding failed due to fact that they were lipophilic and related to nonspecific signal [59, 60].

$^{18}$F-DOPA PET can be used to assess serotonergic and noradrenergic system function and in-
tegrity as both contain AADC. Yet, considering DA terminals also contain a high degree of AADC, the use of $^{18}$F-DOPA PET for non-DA system evaluation should be restricted to regions where a high innervation of serotonin and noradrenaline is established, i.e. the raphe nucleus and locus coeruleus respectively.

Assessment of microglial activation in PD

Microglia are resident immune cells within the central nervous system (CNS) constituting approximately 20% of the total glial population within the brain. Microglia act as the brains’ first line defence mechanism and as such remain in a quiescent state until required to be activated following trauma, ischemia, tumour, inflammation, and neurodegeneration. Peripheral benzodiazepine receptors (PBR) develop on the surface of the mitochondria of activated microglia, therefore the use of the radiotracer, $^{11}$C-PK11195 (a selective marker of peripheral BDZ sites) allows the in vivo measurement of microglia activation and can be used to investigate the contribution of neuroinflammatory glial response in the degenerative process in PD.

A combined $^{11}$C-PK11195 and $^{11}$C-CFT (A DAT marker serving as a tool to measure the density of DA terminals) study in early de novo PD patients has reported that levels of midbrain $^{11}$C-PK11195 binding contralateral to the clinically affected side was significantly higher in the PD group compared to the 10 age-matched healthy controls [61]. Furthermore, midbrain $^{11}$C-PK1195 binding was significantly correlated inversely with $^{11}$C-CFT binding in the putamen and significantly positively correlated with motor disability as measured by the UPDRS. These findings demonstrate that parallel changes in microglia activation correspond with DA terminal loss in the nigrostriatal pathway in early PD, suggesting a role of microglia activation in the progression of PD. A follow up study reported that as the disease progresses, microglia activation as measured by $^{11}$C-PK1195 extends to meso-basal ganglia-thalamo-cortical loop and extrastriatal regions, especially in the occipital cortex [62]. This is suggestive of microglia activation not dissipating as the disease progresses but actually extending beyond the nigrostriatal pathway.

Another study which used both $^{11}$C-PK1195 and $^{18}$F-DOPA PET reported that $^{11}$C-PK1195 binding was significantly increased in the pons, basal ganglia, frontal and temporal cortical regions [63]. It was also reported in the eight PD patients which were examined longitudinally that levels of microglia activation remained stable over two years and did not correlate with clinical severity of disease or with $^{18}$F-DOPA uptake. These results suggest that there is diffuse microglia activation corresponding with the pathological PD process and that microglia may be contributing to the continued degeneration via cytokine release.

Imaging differential diagnosis of PD from other movement disorders

Clinical features of PD may be shared with other disorders, thus creating some issues surrounding the correct diagnosis. For example, multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are often confused with PD at the early stages. Although, essential tremor, drug-induced parkinsonism, corticobasal ganglionic degeneration, dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD) also share common features with PD. Furthermore, some these disorders will initially produces a somewhat mild to moderate response to DA therapy.

PET imaging can be useful in differentiating PD from other disorders. $^{18}$F-DOPA PET has been used to as a utility in the diagnosis of PD, although it is not clear how useful this method is in the differential diagnosis of other parkinsonism disorders [64]. $^{18}$F-DOPA PET has been used to differentiate between post-neuroleptics parkinsonism and idiopathic PD as the former will display intact DA terminals [65]. Furthermore, $^{18}$F-DOPA PET has been applied to disorders other than PD to demonstrate that in PSP, MSA and corticobasal ganglionic degeneration, the average $^{18}$F-DOPA uptake in the caudate nucleus is reduced compared to idiopathic PD patients although putaminal $^{18}$F-DOPA binding is similarly decreased across all disorders [66, 67].

$^{18}$F-FDG PET has been shown to be useful in differentiating PD from MSA (Kwon et al., 2007, 2008). In MSA and PSP, striatal metabolism is low compared to PD patients, where it is either within normal range or increased [42, 66, 68, 69].

RAC PET has also been used in the differential diagnosis of PD from PSP and MSA. It has been reported that PSP and MSA patients show a
PET neuroimaging for PD

putaminal D₂ receptor availability reduction compared to PD patients [70-72].

**Imaging preclinical and genetic forms of PD**

**Preclinical PD**

In order to assess preclinical PD, the subject under investigation must be known to be a carrier of a known causative gene associated with parkinsonism, have a relative with parkinsonism, be an elderly individual with idiopathic hypomnesia or REM sleep behaviour disorders (RBD). The latter two may be harbingers of PD.

The radiotracers DTBZ, ¹¹C-nomifensine, ¹¹C-RT132, ¹¹C-CFT, ¹⁸F-CFT and ¹⁸F-DOPA PET can be used to assess preclinical PD [25, 73, 74]. These studies revealed that DAT binding was the earliest indicator of DA dysfunction in these individuals suggesting that DAT imaging may provide a useful and sensitive tool in detecting subclinical deficits associated with abnormalities in the nigrostriatal pathway. DTBZ PET has also demonstrated the ability to detect nigrostriatal deficits in preclinical PD [75].

An ¹⁸F-DOPA PET study has demonstrated putaminal DA terminal loss in 25% of adult asymptomatic individuals who had family members with PD [76]. Moreover, at a five-year follow up, one third of these individuals went on to develop clinical parkinsonism.

Asymptomatic co-twins of idiopathic PD patients have been studied with ¹⁸F-DOPA PET [77]. This study reported significant putaminal DA terminal loss in both dizygotic co-twins (18%) and monozygotic co-twins (55%). At the four year follow up, advanced putaminal DA terminal loss was observed in all asymptomatic monozygotic co-twins, of which two had developed clinical parkinsonism, whereas, the asymptomatic dizygotic co-twins did not display any advancement in DA denervation.

Carriers of a single parkin mutation have also been assessed with ¹⁸F-DOPA PET where a reported decrease in ¹⁸F-DOPA binding in the putamen, caudate nucleus, and ventral and dorsal midbrain were apparent in the PD group compared to the healthy controls [78]. However, this study did not complete a follow-up so data relating to the progression to clinical parkinsonism is unknown.

Although using PET for the preclinical diagnosis of PD is expensive and not widely available, continued longitudinal follow-up of the asymptomatic at-risk subjects is essential in studying the conversion from preclinical DA dysfunction to clinical disease. As such, an improvement in estimating the duration of the preclinical period can be made as well as increasing understanding of the progression of PD.

**Genetic forms of PD**

PET imaging provides a useful tool is delineating differences between familial and idiopathic PD as it can be difficult to distinguish clinically. The main causative genes implicated in individuals with a family history of PD include autosomal recessive mutations in Parkin (PARK2), PINK1 (PARK6), DJ1 (PARK7) and APT13A2 (PARK9). Autosomal dominant mutations also exist in mutations in alpha-synuclein (PARK1/4), ubiquitin carboxyhydrolase L1-UCH-L1 (PARK5) and leucine rich repeat kinase 2 –LRRK2 (PARK8). All of these mutations can lead to young onset PD.

Both ¹⁸F-DOPA and RAC PET have been used to image genetic forms of PD in comparison to idiopathic PD. These studies have shown that ¹⁸F-DOPA uptake in PARK1/PARK8 compared to idiopathic PD cases is reduced [79, 80]. Furthermore, it has been shown that PARK2, PARK6 and PARK7 PD patients display rather more symmetrical reduction of ¹⁸F-DOPA [81-83] and ¹⁸F-CIT [84] uptake compared to idiopathic PD cases. One of these studies provides further information by demonstrating that reductions in striatal ¹⁸F-DOPA uptake is slower in parkin PD cases compared to idiopathic PD patients [81].

A combined ¹⁸F-DOPA, ¹¹C-PE2I and RAC PET study in a group of young-onset PD patients, with and without parkin mutations, has demonstrated that uptake of all three radiotracers were similar between parkin and non-parkin PD patients [85]. This is suggestive of PET DA markers being indistinguishable between carriers of parkin mutations and other young-onset PD patients with long disease duration.

More recently, an ¹⁸F-DOPA PET study has investigated both symptomatic and asymptomatic parkin PD patients over five years [86]. It was demonstrated that the symptomatic parkin PD
patients showed an annual $^{18}$F-DOPA binding reduction in the putamen of 0.5% and in the caudate nucleus of 2%, compared to asymptomatic parkin PD patients who showed an annual reduction of 0.56% and 0.62% respectively. Another $^{18}$F-DOPA PET study from the same group detected reduced $^{18}$F-DOPA binding in parkin PD patients compared to healthy controls in the caudate nucleus, putamen, ventral striatum, locus coeruleus, midbrain raphe and pallidum [87]. Furthermore, it was shown that the hypothalamus was targeted in idiopathic PD patients compared to the midbrain raphe nuclei in parkin PD patients.

RAC PET has also been applied to genetic forms of PD to assess D$_2$ receptor availability. One study of de novo PD patients has demonstrated increased putaminal RAC binding compared to healthy controls, which displayed similar uptake values to idiopathic PD patients [88]. Furthermore, this study demonstrated that parkin PD patients may be more responsive to DA medication than idiopathic PD cases as by following disease progression (and thus further exposure to DA medication), it was detected in the parkin PD patients that D$_2$ receptor availability significantly decreased in the putamen and caudate nucleus whereas idiopathic PD patients normalized in the same regions.

**Monitoring the progression of PD with PET**

Monitoring the clinical progression of PD can be assessed using $^{18}$F-DOPA PET. However, monitoring progression is complicated by the administration of symptomatic medication, thus disguising the PD symptoms. Furthermore, current scales to assess motor disability are relatively biased towards detecting bradykinesia rather than the other common features of PD. Ideally; studies would aim to assess patients following a period of medication wash-out. However, this is a difficult process due to patient intolerance, and the likelihood that a substantial amount of withdrawal time is required to achieve a successful and complete wash-out of any medication.

Nonetheless, clinical progression has been investigated with $^{18}$F-DOPA PET. It has been reported that $^{18}$F-DOPA uptake in the putamen is correlated with disease progression [20, 21]. Furthermore, that this correlation is particularly related to bradykinesia and rigidity (and not tremor) severity [66]. It is also suggested that DA terminal loss in the caudate nucleus occurs at a slower rate than in the putamen [89].

The ability to monitor PD progression effectively ultimately leads to the ability to track modification of PD progression with DA medications. Some attempts have been made to track the neuroprotective effect of DA agonists, the agents possessing the possible ability to modify disease progression. The REAL PET trial administered either ropinirole or L-DOPA to a cohort of de novo PD patients. This trial demonstrated that patients in the ropinirole group demonstrated a slower reduction of putaminal $^{18}$F-DOPA uptake over two years compared to patients in the L-DOPA group. On the other hand, symptomatic improvement was superior in the L-DOPA group.

However, a different trial utilising $^{18}$F-DOPA PET failed to detect any effect of riluzole, a glutamate inhibitor, in PD progression [90].

**Imaging motor complications in PD**

Currently regular administration of the direct metabolic precursor for DA, L-DOPA, L-3, 4-dihydroxyphenylalanine (L-DOPA) remains the most effective treatment of PD symptomatology. However, long term use often leads to motor fluctuations and the appearance of motor complications such as involuntary movements, so-called L-DOPA-induced dyskinesia (LIDs). The exact underlying mechanisms precipitating these complications are not clear, although it is thought that both pre- and postsynaptic DA systems play a role with further evidence emerging that non-DA systems are also implicated.

To assess the role of presynaptic DA system in motor complications in PD, $^{18}$F-DOPA PET has been utilised in comparing two groups of PD patients; one with a fluctuating motor response to L-DOPA and another with a stable response to L-DOPA. This study reported a 28% decrease in presynaptic terminal function in the putamen of PD patients with a fluctuating response to L-DOPA compared to the stable responders [91]. These results were suggested to be due to i) an inability to store and release DA for use in the nigrostriatal pathway causing motor complications and ii) an altered ‘buffering’ capacity of the DA terminals as a response of differences in nigrostriatal damage between groups. A com-
PET neuroimaging for PD

Combined $^{11}$C-methylphenidate (MP) and DTBZ PET study has shown that putaminal MP/DHBZ is decreased in PD patients with motor fluctuations compared to stable responder PD patients [92]. These data support the hypothesis that presynaptic alterations play a role in the appearance of motor complications in PD due to a continued DAT downregulation, which ultimately leads to an increase in extracellular DA levels.

Postsynaptic DA mechanisms have also been investigated utilizing $^{11}$C-SCH23390 and RAC PET as measures of the D1 and D2 receptor subtype availability respectively comparing a group of stable responder PD patients and fluctuating responder PD patients [40, 93]. However, the findings from these studies reported that mean D1 receptor availability was within the normal range in the caudate nucleus and putamen and mean D2 receptor availability in the putamen at baseline for both groups. Mean D2 receptor availability was reduced by approximately 15% within the caudate nucleus for both groups suggesting that this reduction may not be a precipitating factor of motor complications but an observation of disease progression. RAC PET used in conjunction with an L-DOPA challenge can monitor striatal DA release alterations. An early study reported a decrease of 23% in putaminal RAC binding following a single L-DOPA dose in PD patients with motor complications compared to stable responders [94]. Furthermore, UPDRS scores during the ‘off’ medication state were inversely correlated with the reduction of putaminal RAC binding suggestive of an increasing inability to regulation DA release effectively as the disease progresses in patients with a fluctuating response to L-DOPA. A further RAC PET study reported that synaptic DA levels were three times higher in patients with motor fluctuations compared to stable responders following a single dose of L-DOPA [91]. Furthermore, UPDRS scores were corresponded with increases in synaptic DA levels. More specifically, it was reported that bradykinesia and rigidity scores were correlated with putaminal DA release, whereas tremor scores were not.

Non-DA systems have also received some attention regarding the pathophysiology of motor fluctuations and dyskinesias development. $^{11}$C-diprenorphine, a marker of μ, κ and δ opioid sites, has demonstrated that binding was reduced in both striatal (caudate nucleus and putamen) and extra-striatal (thalamus and anterior cingulate) in PD patients experiencing LID compared to stable responders [76]. Neurokinin-1 (NK1) receptor availability has been assessed in vivo with $^{18}$F-L829165 and reported that thalamic NK1 receptor availability in patients with LID was reduced [95]. A preliminary $^{11}$C-SCH442416 PET study (marker for A2A receptors) in an attempt to assess the adenosine systems has revealed that a significant increase of striatal A2A binding in patients with LID compared to patients without LID and healthy controls which had a similar degree of binding [96]. The authors also reported that thalamic A2A binding was similar across all three groups and suggest that the use of A2A receptor agonists in the clinical management of LID is justified. Only one study to date has examined the glutamatergic system in vivo with $^{11}$C-CNS5161 PET, which binds to the MK801 site. This two-scan (one ‘on’ medication and one ‘off’ medication) study had 18 PD patients divided into one group with LID and one group of stable responders. It was reported that binding was reduced in the caudate nucleus, putamen and motor cortex of the stable responders suggesting that the PD LID group may have relatively enhanced glutamate receptor activity in these areas [97]. Finally, the role of serotonin terminals potentially mishandling exogenous L-DOPA and subsequently releasing DA as a false neurotransmitter in LID has recently been assessed in vivo in patient groups for the first time using RAC PET and suprathreshold L-DOPA and buspirone (5-HT1A agonist) challenges. The authors demonstrated in 16 PD patients with LID that buspirone administration which precedes L-DOPA administration, led to a reduction in putaminal RAC binding compared to the L-DOPA challenge and to the stable responders [98]. This is in contrast to the stable responders who appeared to be unaffected following the buspirone challenge. Clinically, the PD LID group demonstrated attenuation of LID following administration of buspirone. These findings indicate that serotonin terminals are likely to play a key role in LID, thus justifying the use of 5-HT agonists in the clinic in order to dampen the excessive DA release and as such attenuate LID.

Contribution of PET in restorative therapeutic strategies

The aim of restorative approaches in PD is to restore DA function in the affected areas. Potential strategies to achieve this include transplan-
tation of striatal grafts of human or fetal mesencephalic cells, stem cells, gene therapy and nerve growth factors.

$^{18}$F-DOPA PET can be used to monitor the outcome of striatal graft transplantations in humans. This technique has shown that $^{18}$F-DOPA uptake increases in the striatum following the transplantation [77, 99] (Figure 3). Furthermore, it has been demonstrated with $^{18}$F-DOPA PET that transplantation of midbrain fetal cells into the putamen of PD patients' results in graft survival of up to ten years and the ability to release DA following a methamphetamine challenge is normalised [77]. Moreover, activation of the dorsolateral prefrontal cortex (DLFPC) and supplementary motor area (SMA) is restored [100].

Two double-blind trials have been conducted to assess the efficacy of human fetal transplants [101, 102]. However, although the $^{18}$F-DOPA binding levels appeared to be successfully restored there did not appear to be any clinical improvement amongst the transplanted PD patients. One of the most troubling side effects of these trails was the emergence of graft-induced dyskinesias (GID). It has been suggested that the transplanted grafts were over-producing DA, thus causing the GID [103]. However, there were suggestions that other factors played a role [104, 105].

Glial cell line-derived neurotrophic factor (GDNF) infusion has been infused into the putamen of PD patients. It is established that GDNF protect DA neurons in rodents and non-human primates and $^{18}$F-DOPA PET has been used to assess it efficacy in humans [106]. It was shown that $^{18}$F-DOPA uptake increased in line with UPDRS scores over 12 months, suggesting that the use of GDNF may be a viable restorative approach in PD.

Finally, the suggestion that GID pathogenesis is related to the serotonergic system has been recently assessed for the first time utilising $^{11}$C-DASB PET. Two patients with good recovery of motor symptoms but who developed GID following neural transplantation were studied and demonstrated excessive serotonergic innervation in the grafted striatum [107]. The patients demonstrated an increase of $^{11}$C-DASB binding of 172% and 285% each compared to the mean binding values of the non-transplanted PD patients and healthy controls. The degree of serotonergic hyperinnervation in the two transplanted patients was consistent with the size of graft originally transplanted and severity of GID, i.e. the patient who received 42% more tissue than the other patient demonstrated more serotonergic hyperinnervation as well as more severe GIDs. It was also discovered that the ratio of serotonergic to DA innervation (as measured by $^{11}$C-DASB and $^{18}$F-DOPA binding) was increased up to 230% compared to healthy controls. Furthermore, the authors attempted to address the claim that serotonin terminals possess the ability to convert L-DOPA to DA, thus acting as a false neurotransmitter by administering the 5-HT$_{1A}$ agonist, buspirone, to the two patients.
transplanted patients. Indeed, GIDs were successfully attenuated following the administration of buspirone, indicating that the motor complications arose from serotonergic hyperinnervation and dysregulated release of DA in the grafted striatum.

**Contribution of PET for the assessment of non-motor symptoms**

**Sleep and fatigue**

Sleep disorders in PD manifest in a variety of forms including, disruptions in nocturnal sleep, insomnia and excessive daytime sleepiness (EDS) that often occurs due to the two former sleep disruptions mentioned.

\( { }^{18} \text{F}-\text{DOPA} \) PET has been used to study PD patients with sleep problems [108]. This study reported a significant inverse correlation between \( { }^{18} \text{F}-\text{DOPA} \) uptake in the mesopontine and rapid eye movement (REM) sleep as measured by polysomnography. This finding indicates that monominergic activity in the mesopontine may be related to the inability to maintain nocturnal REM sleep in PD patients.

Disabling fatigue is estimated to occur in approximately one third of PD patients [109]. To date only one PET study has been conducted which specifically investigated fatigue in PD [8]. This combined \( { }^{18} \text{F}-\text{DOPA} \) and \( { }^{11} \text{C}-\text{DASB} \) PET study sought to investigate both the DA and serotonergic systems in a group of PD patients with and without fatigue. Results from a region of interest analysis approach indicate that the PD group with fatigue showed significantly reduced \( { }^{11} \text{C}-\text{DASB} \) binding compared to the PD group without fatigue in the putamen, caudate nucleus, ventral striatum and thalamus. However, \( { }^{18} \text{F}-\text{DOPA} \) uptake was similar in all regions in both groups. A voxel based analysis revealed further reductions of \( { }^{11} \text{C}-\text{DASB} \) binding in the cingulate and amygdala and further \( { }^{18} \text{F}-\text{DOPA} \) binding reductions in the caudate and insula in the PD group with fatigue. The authors suggest that these results are indicative of a possible association between fatigue in PD with reduced serotonergic function in the basal ganglia and limbic structures as well as a possible insular DA dysfunction.

**Depression**

Depression in PD is reported to occur in approximately 45% of patients, however the pathophysiology is unclear. It is also not clear if depression in PD may be part of the disease course for certain patients or in fact a reaction of the patient due to the diagnosis itself. Because Lewy body pathology is known to effect the serotonergic, noradrenergic and DA systems, it is possible that dysfunction in any of these systems may be responsible for the occurrence of depression in PD.

\( { }^{11} \text{C}-\text{RTI} \ 32 \) PET is a marker of both DAT and noradrenergic transporter binding. A study utilizing this radiotracer showed that PD patients without depression demonstrated reduced putaminal \( { }^{11} \text{C}-\text{RTI} \ 32 \) uptake, but PD patients with depression demonstrated additional reductions in the noradrenergic locus coeruleus, thalamus, and the limbic system (amygdala, ventral striatum, and anterior cingulate) [4]. Severity of anxiety inversely correlates with \( { }^{11} \text{C}-\text{RTI} \ 32 \) binding in these regions. These results suggest that depression in PD may be associated with noradrenergic and limbic DA denervation in addition to striatal DA denervation.

\( { }^{123} \beta-\text{CIT} \) is a radiotracer, which binds with nanomolar affinity to DA, noradrenaline, and serotonin transporters. One study using \( { }^{123} \beta-\text{CIT} \) PET in PD patients with depression found no binding differences between patients with and without depression or between binding and Hamilton Depression Rating Scale scores (HDRS) [51].

Altered serotonergic neurotransmission in PD patients with depression has been investigated using \( { }^{11} \text{C}-\text{WAY100635} \) PET [49]. This study reported that despite a decrease in 5-HT1A binding in the raphe nucleus or PD patients compared to controls, there was no difference between depressed and non-depressed PD patients.

One \( { }^{11} \text{C}-\text{DASB} \) PET study has reported an increase in 5-HTT binding in the OFC region of depression patients with early PD [110].

More recently, another study utilising \( { }^{11} \text{C}-\text{DASB} \) PET has reported a relationship between PD patients exhibiting depressive symptoms and 5-HTT binding in limbic regions and the raphe nucleus [111]. This study used a cohort of 34 antidepressant-naïve PD patients and 10 matched healthy controls. Depressive symptoms were systematically assessed using the Beck Depression Inventory-II (BDI-II), HRDS and a structured...
PET neuroimaging for PD

Clinical interview for DSM – IV Axis I Disorders (SCID-I). It was demonstrated that PD patients with depressive symptoms, had significantly increased $^{11}$C-DASB binding in the amygdale, hypothalamus, caudal raphe nuclei and posterior cingulate cortex. Furthermore, all other brain regions demonstrated similarly decreased $^{12}$C-DASB binding in both the high and low depressive symptom PD groups compared to healthy controls. The authors suggest that raised 5-HTT availability in limbic areas is implicated in the pathophysiology of depression in PD and justifies the use of agents acting on 5-HTT in the treatment of PD depression.

Dementia

The presence of dementia in PD is estimated to be approximately 40% [112]. PET imaging has been used to investigate both DA and cholinergic dysfunction in PD patients with dementia.

$^{18}$F-DOPA PET has been used to compare mesofrontal DA projections in PD patients and PD patients with dementia (PDD). All patients were matched for age, disease duration and disease severity and both groups showed a similar level of $^{18}$F-DOPA binding in the putamen [113]. However, the PDD group showed additional reductions in the right caudate and bilaterally in the ventral striatum and the anterior cingulate, suggesting a potential role of mesolimbic and mesocortical dysfunction in demented PD patients.

$^{18}$F-FDG PET studies have indicated that there is a pattern of reduced glucose metabolism in frontal, temporal and parietal areas when comparing PDD and AD patients [7, 114, 115]. Furthermore, comparing PDD patients and patients with dementia Lewy bodies (DLB), both groups appear to display hypometabolism in parietal, temporal, occipital, frontal areas and in the anterior cingulate when they are compared to healthy controls. Although when PDD and DLB groups are directly compared, hypometabolism in the anterior cingulate is more pronounced in the DLB group [116].

Cholinergic dysfunction has been investigated using the radiotracers; $^{11}$C-PMP and $^{11}$C-MP4A, which can be used to assess acetylcholinesterase (AChE) activity. An $^{11}$C-MP4A PET study has reported a reduction in cortical binding in PD patients of 11% which increases to 30% in PDD patients (particularly in parietal areas) [117].

An $^{11}$C-MP4A PET study has reported that $^{11}$C-MP4A binding correlated with levels of striatal $^{18}$F-DOPA uptake in a group of PD patients with and without dementia [54]. This is suggestive of a parallel reduction in DA and cholinergic function in PD. Interestingly; cortical AChE deficiency correlated with cognitive testing scores but did not correlate with motor symptoms. This is suggestive of a dysfunctional cholinergic system contributing to PDD.

$^{11}$C-PIB PET has been utilised in determining the prevalence of raised amyloid load in DLB and PDD. This study reported that 11/13 DLB and 2/13 PDD patients has significantly raised amyloid plaque levels, therefore, it may not be a factor in the development of PDD [118].

Psychosis

Visual hallucinations are the most common form of psychosis observed in PD, which tend to occur later in the disease stage alongside some form of cognitive impairment. PET studies investigating psychosis in PD is limited.

$^{18}$F-FDG PET has been used to investigate visual hallucinations in PD [12]. This study reported that the frontal areas, and in particular, the superior frontal gyri demonstrated increased cerebral glucose metabolic rate in PD patients with visual hallucinations compared to PD patient without any form of visual hallucinations. More recently, the radiotracer, $^{18}$F-setoperone, a selective marker for the serotonin 2A receptor, has been implemented in a pilot study of seven PD patients with visual hallucinations and seven age and sex matched PD controls without any history of visual hallucinations [119]. This study reported that increased $^{18}$F-setoperone binding mainly clustered in the ventral visual pathway, including the bilateral inferooccipital gyrus, right fusiform gyrus, and inferotemporal cortex. Binding increases were also detected bilaterally in the insula and dorsolateral prefrontal cortex.

Impulse control disorders and dopamine dysregulation syndrome

DA medications, including L-DOPA are the most effective method of PD symptom management. However, following long-term use of DA medica-
tions, it has now become apparent that addictive and compulsive behaviours are associated with chronic treatment [120]. The most commonly seen maladaptive behaviours in clinic include punding and the so-called impulse control disorders (ICDs); hypersexuality (HS), pathological gambling (PG), compulsive shopping (CS), binge eating (BE). Also seen, although to a lesser extent is the phenomenon, dopamine dysregulation syndrome (DDS) which is a consequence of the patient becoming addicted to their DA medication with an increased degree of craving [121], thus seeking to self-administer without the clinicians’ knowledge. These behaviours are difficult to manage as often they are not apparent to the patient’s family or to the clinician until they have become quite advanced, often due to the patient themselves concealing the acquired behaviours. Once the issue becomes apparent they require immediate attention.

DDS has been investigated using RAC PET [122]. It has been demonstrated that following an L-DOPA challenge, DDS PD patients have increased DA release in the ventral striatal areas compared to a group of PD patients without DDS. Furthermore, RAC binding in the DDS group correlated with an increase in ‘wanting’ and not ‘liking’ the drug indicative of an addictive behaviour. It is suggested that this finding is consistent with the theory of incentive sensitisation of compulsive drug use. This theory suggests that compulsive drug use occurs due to an increased attribution of incentive salience for rewards (via drug use) due to mesolimbic neuro-circuitry adaptations [123].

Recently, ICDs have begun receiving attention. Another RAC PET study with a PD cohort consisting of two groups, one with PD patients with either DDS or an ICD (n= 11) and another PD group without DDS or ICDs (n= 7) has been recently published [10]. This study conducted three RAC PET scans; one while patients were in the ‘off’ medication state and were exposed to neutral cues, another one while patients were in the ‘on’ medication state and exposed to the neutral cues and a third which consisted of the patients being in an ‘on’ medication state and exposed to reward-related cues. During the ‘on’ scans, the patients were administered an oral dose of L-DOPA. It was reported that patients with DDS or ICD demonstrated a greater decrease of RAC binding in the ventral striatum compared to the PD patients without any evidence of DDS or ICD during the scan with reward cues. This group difference was not observed during the L-DOPA challenge alone scan. The authors suggest that their findings are consistent with the incentive sensitisation theory.

PG in PD has been investigated with RAC PET using a gambling task [124]. It was reported that patients with PG showed greater decreases in RAC binding in the ventral striatum during gambling (13.9%) compared to control patients (8.1%), suggesting greater DA release.

An H215O PET study has also been conducted in PD patients with PG [125]. It was reported that a reduction in cerebral blood flow in lateral orbitofrontal cortex, rostral cingulate, amygdala and pallidum was detected following administration of DA medication.

Cardiac sympathetic denervation

It has been reported that most patients with idiopathic PD show a significant loss of sympathetic innervation of the heart [126]. Myocardial denervation in early PD patients has been detected even when cardiovascular reflexes are still intact. Cardiac sympathetic denervation may contribute to symptoms of autonomic failure such as orthostatic hypotension.

The only PET study to investigate orthostatic hypotension in PD has utilised 11C-MHED PET [127] which is able to visualise sympathetic neurons. This study reported 11C-MHED uptake was reduced in PD patients compared to healthy controls. Furthermore, PD patients with orthostatic hypotension displayed further reduction in 11C-MHED uptake.

Olfactory function

Olfactory dysfunction is a frequent non-motor symptom of PD, which has been attributed to early pathological deposition of Lewy bodies, and Lewy neurites in primary olfactory centers and involves deficits in odor detection, discrimination and identification [128]. Hyposmia may be related to neuronal degeneration with deposition of alpha-synuclein in primary olfactory areas as a very early component of the pathology of PD [129, 130].

11C-CFT PET has been utilised in the investigation of DA denervation in the nigrostriatal pathway and olfactory deficits in PD [131]. It was
reported that reduced $^{11}$C-CFT in the nigrostriatal pathway was more pronounced in a group of PD patients with olfactory dysfunction compared to a group of healthy controls. Furthermore, uptake values correlated with poorer smell identification scores.

More recently, a study using the same method has reported that selective hyposmia in PD is mostly correlated with hippocampal rather than amygdala, ventral or dorsal striatal DA innervation as measured by $^{11}$C-CFT binding. These findings are suggestive of a hippocampal mesolimbic DA involvement in selective hyposmia in PD.

Conclusions

PET imaging has provided an excellent tool to investigate the many facets of PD in vivo. The technique has increased understanding surrounding the differential diagnosis of PD, the progression of the disease, complications arising from DA medications, as well as the non-motor symptoms of the disease. Furthermore, PET imaging will allow greater advancement of alternative restorative approaches to therapy in PD as it can be used to evaluate the efficacy of a therapy and monitor improvements (or declines) longitudinally.

However, there are many gaps in our knowledge still remaining, which could be closed by using PET imaging techniques. Future PET studies should focus on understanding the role of non-DA neurotransmitter systems in not only the pathogenesis of the PD motor disease and arising medication related complications, but also the non-motor features, such as addiction and compulsion as they greatly impact on the quality of life of PD patients.

Of course, to achieve all of this, new radiotracers need to be developed for biological specificity and to enable us to image chemical pathways, which are currently out of reach, such as noradrenergic function.

Address correspondence to: Dr. Marios Politis, Hammersmith Hospital, DuCane Road, London W12 0NN, United Kingdom; Tel: +44-020-8383-3751; E-mail: marios.politis@imperial.ac.uk

References

[16] Kuzuhara S, Mori H, Izumiyama N, Yoshimura
PET neuroimaging for PD


PET neuroimaging for PD


PET neuroimaging for PD


PET neuroimaging for PD


PET neuroimaging for PD


PET neuroimaging for PD


